208 related articles for article (PubMed ID: 31881859)
1. Time to viral load suppression and its associated factors in cohort of patients taking antiretroviral treatment in East Shewa zone, Oromiya, Ethiopia, 2018.
Ali JH; Yirtaw TG
BMC Infect Dis; 2019 Dec; 19(1):1084. PubMed ID: 31881859
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Immunological and Virological Outcomes in Children Receiving Highly Active Antiretroviral Therapy at Hawassa University College of Medicine and Health Sciences, Southern Ethiopia.
Fenta DA; Wube TB; Nuru MM
J Immunol Res; 2021; 2021():2498025. PubMed ID: 33928167
[TBL] [Abstract][Full Text] [Related]
3. HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study.
Desta AA; Woldearegay TW; Futwi N; Gebrehiwot GT; Gebru GG; Berhe AA; Godefay H
BMC Infect Dis; 2020 Jan; 20(1):4. PubMed ID: 31898535
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Time to Viral Load Suppression of Adult PLWHIV on ART in Arba Minch General Hospital: A Follow up Study.
Hussen S; Mama M; Mekonnen B; Yihune M; Shegaze M; Boti N; Shure M
Ethiop J Health Sci; 2019 Nov; 29(6):751-758. PubMed ID: 31741646
[TBL] [Abstract][Full Text] [Related]
5. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
6. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.
Ledergerber B; Lundgren JD; Walker AS; Sabin C; Justice A; Reiss P; Mussini C; Wit F; d'Arminio Monforte A; Weber R; Fusco G; Staszewski S; Law M; Hogg R; Lampe F; Gill MJ; Castelli F; Phillips AN;
Lancet; 2004 Jul 3-9; 364(9428):51-62. PubMed ID: 15234856
[TBL] [Abstract][Full Text] [Related]
7. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
[TBL] [Abstract][Full Text] [Related]
8. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
[TBL] [Abstract][Full Text] [Related]
9. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
10. Risk of triple-class virological failure in children with HIV: a retrospective cohort study.
; Castro H; Judd A; Gibb DM; Butler K; Lodwick RK; van Sighem A; Ramos JT; Warsawski J; Thorne C; Noguera-Julian A; Obel N; Costagliola D; Tookey PA; Colin C; Kjaer J; Grarup J; Chene G; Phillips A
Lancet; 2011 May; 377(9777):1580-7. PubMed ID: 21511330
[TBL] [Abstract][Full Text] [Related]
11. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Survival among Adult Ethiopian Patients in the National ART Program at Seven University Teaching Hospitals: A Prospective Cohort Study.
Fekade D; Weldegebreal T; Teklu AM; Damen M; Abdella S; Baraki N; Belayhun B; Berhan E; Kebede A; Assefa Y
Ethiop J Health Sci; 2017 Feb; 27(Suppl 1):63-71. PubMed ID: 28465654
[TBL] [Abstract][Full Text] [Related]
13. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
[TBL] [Abstract][Full Text] [Related]
14. Immunological and virological discordance among people living with HIV on highly active antiretroviral therapy in Tigray, Northern Ethiopia.
Hailu GG; Wasihun AG
BMC Infect Dis; 2021 Jun; 21(1):561. PubMed ID: 34118891
[TBL] [Abstract][Full Text] [Related]
15. Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.
O'Connor JL; Smith CJ; Lampe FC; Hill T; Gompels M; Hay P; Chadwick D; Fisher M; Ainsworth J; Gilson R; Mackie N; Anderson J; Orkin C; Nelson M; Kegg S; Leen C; Palfreeman A; Post F; Johnson M; Sabin CA; Phillips AN;
AIDS; 2014 Mar; 28(6):919-24. PubMed ID: 24335482
[TBL] [Abstract][Full Text] [Related]
16. First line antiretroviral treatment failure and associated factors among people living with HIV in northwest Ethiopia.
Genet A; Mekonnen Z; Yizengaw E; Mekonnen D
Afr Health Sci; 2021 Mar; 21(1):263-272. PubMed ID: 34394306
[TBL] [Abstract][Full Text] [Related]
17. Interferon-γ-Inducible Protein 10 (IP-10) Kinetics after Antiretroviral Treatment Initiation in Ethiopian Adults with HIV.
Thorman J; Björkman P; Marrone G; Tolera Balcha T; Tesfaye F; Abdissa T; Naniche D; Medstrand P; Reepalu A
Microbiol Spectr; 2021 Dec; 9(3):e0181021. PubMed ID: 34908450
[TBL] [Abstract][Full Text] [Related]
18. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children.
Mulu A; Liebert UG; Maier M
BMC Infect Dis; 2014 Jan; 14():28. PubMed ID: 24422906
[TBL] [Abstract][Full Text] [Related]
19. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.
Meyer JP; Cepeda J; Wu J; Trestman RL; Altice FL; Springer SA
JAMA Intern Med; 2014 May; 174(5):721-9. PubMed ID: 24687044
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
Bai R; Lv S; Hua W; Su B; Wang S; Shao Y; Li Z; Liu A; Sun L; Dai L
HIV Med; 2022 Mar; 23 Suppl 1():72-83. PubMed ID: 35293102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
